BIOMARKER:

No biomarker

News alerts, weekly reports and conference planners

No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab Sensitive: A2 - Guideline PMLive - 4 days (New A2) pembrolizumab Sensitive : A2 PMLive - 4d	pembrolizumab Sensitive: A2 - Guideline PMLive - 4 days pembrolizumab Sensitive : A2 PMLive - 4 days - (New A2)
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	toripalimab Sensitive: A1 - Approval GlobeNewswire - 6 days (New A1) toripalimab Sensitive : A1 GlobeNewswire - 6d	toripalimab Sensitive: A1 - Approval GlobeNewswire - 6 days toripalimab Sensitive : A1 GlobeNewswire - 6 days - (New A1)
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval BeiGene Press Release - 1 week (New A2) zanubrutinib Sensitive : A1 BeiGene Press Release - 1wk	zanubrutinib Sensitive: A1 - Approval BeiGene Press Release - 1 week zanubrutinib Sensitive : A1 BeiGene Press Release - 1 week - (New A2)
No biomarker	Melanoma	No biomarker	Melanoma	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 1 week (New A1) pembrolizumab Sensitive : A1 Merck (MSD) Press Release - 1wk	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 1 week pembrolizumab Sensitive : A1 Merck (MSD) Press Release - 1 week - (New A1)
No biomarker	T Cell Non-Hodgkin Lymphoma	No biomarker	T Cell Non-Hodgkin Lymphoma	sugemalimab Sensitive: B - Late Trials CStone Pharma Press Release - 1 week (New B) sugemalimab Sensitive : B CStone Pharma Press Release - 1wk	sugemalimab Sensitive: B - Late Trials CStone Pharma Press Release - 1 week sugemalimab Sensitive : B CStone Pharma Press Release - 1 week - (New B)
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	envafolimab Sensitive: B - Late Trials Tracon Pharmaceuticals Press Release - 1 week (New B) envafolimab Sensitive : B Tracon Pharmaceuticals Press Release - 1wk	envafolimab Sensitive: B - Late Trials Tracon Pharmaceuticals Press Release - 1 week envafolimab Sensitive : B Tracon Pharmaceuticals Press Release - 1 week - (New B)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval Lancet Oncol - 2 weeks (New B) pembrolizumab Sensitive : A1 Lancet Oncol - 2wk	pembrolizumab Sensitive: A1 - Approval Lancet Oncol - 2 weeks pembrolizumab Sensitive : A1 Lancet Oncol - 2 weeks - (New B)
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide capsule Sensitive: A1 - Approval FDA - 2 weeks (New A1) enzalutamide capsule Sensitive : A1 FDA - 2wk	enzalutamide capsule Sensitive: A1 - Approval FDA - 2 weeks enzalutamide capsule Sensitive : A1 FDA - 2 weeks - (New A1)
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	XMT-1660 Sensitive: B - Late Trials Mersana Therapeutics Press Release - 2 weeks (New B) XMT-1660 Sensitive : B Mersana Therapeutics Press Release - 2wk	XMT-1660 Sensitive: B - Late Trials Mersana Therapeutics Press Release - 2 weeks XMT-1660 Sensitive : B Mersana Therapeutics Press Release - 2 weeks - (New B)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval Lancet Oncol - 3 weeks (New B) pembrolizumab Sensitive : A1 Lancet Oncol - 3wk	pembrolizumab Sensitive: A1 - Approval Lancet Oncol - 3 weeks pembrolizumab Sensitive : A1 Lancet Oncol - 3 weeks - (New B)
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	durvalumab Sensitive: A1 - Approval FDA - 3 weeks (New A1) durvalumab Sensitive : A1 FDA - 3wk	durvalumab Sensitive: A1 - Approval FDA - 3 weeks durvalumab Sensitive : A1 FDA - 3 weeks - (New A1)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	fluorouracil topical Sensitive: A1 - Approval fluorouracil topical Sensitive : A1	fluorouracil topical Sensitive: A1 - Approval fluorouracil topical Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1

No biomarker

Associations